{"id":"NCT02348632","sponsor":"Jazz Pharmaceuticals","briefTitle":"\"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA\"","officialTitle":"A Long-Term Safety and Maintenance of Efficacy Study ofJZP-110 [(R)-2-amino-3 Phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or Obstructive Sleep Apnea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05","primaryCompletion":"2017-12","completion":"2017-12","firstPosted":"2015-01-28","resultsPosted":"2019-06-25","lastUpdate":"2019-06-25"},"enrollment":645,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Narcolepsy","Obstructive Sleep Apnea"],"interventions":[{"type":"DRUG","name":"JZP-110","otherNames":[]}],"arms":[{"label":"75 mg - 300 mg of JZP-110","type":"OTHER"}],"summary":"This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05 201, or ADX-N05 202.","primaryOutcome":{"measure":"Change in Epworth Sleepiness Scale (ESS) Score","timeFrame":"Start of randomized withdrawal phase to end of randomized withdrawal (2 weeks)","effectByArm":[{"arm":"JZP-110","deltaMin":1.6,"sd":0.41},{"arm":"Placebo","deltaMin":5.3,"sd":0.41}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":80,"countries":["United States","Canada","Finland","France","Germany","Netherlands"]},"refs":{"pmids":["36084494","34606437","33179591","31691827"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":643},"commonTop":["Headache","Nausea","Nasopharyngitis","Insomnia","Dry mouth"]}}